Alebund Pharmaceutical
Alebund Pharmaceutical raises $75M Series C at $500M valuation
Alebund Pharmaceutical: Series C Funding Round
Alebund Pharmaceutical has successfully raised $75M in Series C funding, reaching a valuation of $500M.
Company Overview
Renal disease therapeutics
Funding Details
The Series C round was led by Kingray Capital, with participation from Yangzhou Guojin.
Company Information
- Headquarters: Shanghai, China
- Founded: 2018
- Employees: 150+
- Category: HealthTech
Investment
Alebund Pharmaceutical plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Kingray Capital: Verified investor in Series C
- Yangzhou Guojin: Verified investor in Series C
Company Info
Investors (2)
Share
Related Reports
Abridge Raises $150M Series C to Transform HealthTech
Abridge has secured $150M Series C in funding to accelerate growth and innovation in the healthtech sector. Medical AI scribe platform automatically documenting patient-provider conversations and generating clinical notes...
Innovaccer Raises $275M Series F to Transform HealthTech
Innovaccer has secured $275M Series F in funding to accelerate growth and innovation in the healthtech sector. Healthcare data platform unifying patient data and providing analytics for value-based care and population health manage...
Truveta Raises $95M Series B to Transform HealthTech
Truveta has secured $95M Series B in funding to accelerate growth and innovation in the healthtech sector. Healthcare data platform aggregating de-identified patient records to accelerate medical research and drug development...
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free